WuXi Biologics Lands on Forbes China ESG 50 List for Green CRDMO Leadership
Event summary
- WuXi Biologics named to the 2026 Forbes China ESG 50 list for its Green CRDMO solutions and ESG digital innovation.
- The company achieved a 30% reduction in Scope 1 and Scope 2 greenhouse gas emission intensity compared to 2020.
- WuXi Biologics reduced water intensity by 32% compared to 2019, exceeding its original 30% target.
- The company has established a comprehensive ESG data governance system covering its global operations.
- WuXi Biologics has developed a digital Smart ESG platform for refined and standardized information collection and governance.
The big picture
WuXi Biologics' inclusion in the Forbes China ESG 50 list underscores the growing importance of ESG performance in the biopharmaceutical industry. The company's focus on Green CRDMO solutions and digital ESG innovation aligns with broader trends towards sustainable development and data-driven governance. With over 14,000 employees and a global footprint, WuXi Biologics is positioning itself as a leader in empowering partners to achieve their sustainability goals.
What we're watching
- Green Technology Adoption
- How WuXi Biologics' Green CRDMO solutions will influence industry-wide adoption of sustainable biopharmaceutical manufacturing practices.
- ESG Digital Innovation
- Whether the company's Smart ESG platform can set a new standard for ESG data governance in the biopharmaceutical sector.
- Regulatory Compliance
- The pace at which WuXi Biologics can maintain its leadership position as ESG regulations and compliance requirements evolve.